Table 3.
Clinico-pathologic characteristics of patients included in the study (63 tumor cohort).
| Parameter | Status | Number (%) |
|---|---|---|
| Age | <30 | 1 (2.1) |
| (Median: 45) | 30–40 | 11 (22.9) |
| (Range: 29–49) | 41–49 | 36 (75) |
| Tumor Stage | stage 1 | 26 (54.2) |
| stage 2 | 16 (33.3) | |
| stage 3 | 1 (2.1) | |
| stage 4 | 1 (2.1) | |
| Unknown | 4 (8.3) | |
| Tumor Grade a | Grade I | 8 (12.7) |
| Grade II | 23 (36.5) | |
| Grade III | 32 (50.8) | |
| LVI | Absent | 42 (64.3) |
| Present | 15 (35.7) | |
| Number of positive lymph nodes | 0 | 21 (60) |
| 1–3 | 11 (31.4) | |
| 4–10 | 1 (2.9) | |
| >10 | 2 (5.7) | |
| ER Status | Negative | 14 (29.2) |
| Positive | 34 (70.8) | |
| PR Status | Negative | 12 (25) |
| Positive | 36 (75) | |
| HER2 Status b | Negative | 36 (75) |
| Positive | 9 (18.8) | |
| Missing value | 3 (6.2) | |
| ER/PR/HER2 Status | Triple negative | 10 (14) |
| Others | 53 (86) | |
| Survival | Positive | 11 (17) |
| Negative | 43 (68) | |
| Missing value | 9 (15) |
a Tumor grade is determined based on SBR score (See Experimental Section); b HER2 staining was scored using the Hercept test® scoring system (See Experimental Section).